OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
7
Results
Show all
Save search
Copy query
Show results for
Unknown
(7)
Release Date
2021
(2)
2022
(1)
2019
(1)
2018
(1)
2016
(1)
2013
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Not available
S-EPMC8949717
|
biostudies-literature
Cite
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Not available
S-EPMC8554687
|
biostudies-literature
Cite
Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2).
Not available
S-EPMC3706107
|
biostudies-literature
Cite
The Association of Statin Use with Cataract Progression and Cataract Surgery: The AREDS2 Report Number 8.
Not available
S-EPMC4808327
|
biostudies-literature
Cite
Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.
Not available
S-EPMC6246813
|
biostudies-literature
Cite
Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17.
Not available
S-EPMC6348044
|
biostudies-literature
Cite
Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial.
Not available
S-EPMC8532036
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets